Cronos Group's decision to exit its U.S. hemp-derived CBD operations is aimed at improving cash flow and positioning the company for entry into the U.S. THC market when regulatory conditions change. While this move may have a positive impact on the company's financial position in the long term, the short-term impact on the stock price is uncertain, as it depends on market perception and the timeline for regulatory changes.